Piramal Pharma Reports ₹5 Crore Profit in Q2, Revenue Up 28%

MUMBAI — Piramal Pharma has reported a consolidated net profit of ₹5 crore for the July-September quarter of the current fiscal year, according to a regulatory filing released by the company.

The performance marks a recovery for the Mumbai-based pharmaceutical firm, which had posted a net loss of ₹99.22 crore in the corresponding period of the previous financial year.

During the second quarter, the company's revenue from operations increased to ₹2,617.06 crore. This represents a 28 percent growth compared to the ₹2,043.72 crore reported in the same quarter last year.

Alongside the rise in revenue, the company's total expenses also saw an upward movement. Total expenses grew to ₹2,589.10 crore in the September quarter, compared to ₹2,170.29 crore recorded in the corresponding period of the previous year.

Following the financial announcement, shares of Piramal Pharma settled 1.69 percent higher at ₹198.45 apiece on the Bombay Stock Exchange (BSE).

"Piramal Pharma's return to profitability in the second quarter highlights a positive trajectory driven by top-line expansion. Growing revenue by 28 percent while managing operational expenses is a critical balance for manufacturing and life sciences companies aiming for sustainable financial health. Investors will likely monitor how the firm maintains this margin discipline as it scales its operations further in the coming quarters." — Dr. Shishir Gupta, Founder & CEO, StartupLanes